Multiple sclerosis is quietly shifting how drugmakers define success. Instead of judging a therapy mainly by whether it reduces relapses, developers are chasing the slower, harder-to-treat processes that drive long-term disability, and Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is one of the companies building a therapy around that shift, through its myelin-focused candidate Lucid-MS.
For decades, MS treatment success was measured largely by relapse rates. Fewer flare-ups meant a drug was working. But researchers now recognize that a substantial proportion of long-term disability accumulates independent of relapses altogether, a phenomenon researchers call progression independent of relapse activity (PIRA). That shift has forced researchers to look at what is actually driving PIRA. A major suspect is chronic active lesions, sometimes called smoldering or mixed active-inactive lesions.
Rather than broadly suppressing the immune system, Quantum BioPharma's Lucid-MS is designed to inhibit myelin degradation, preserve myelin and support functional recovery. By targeting these mechanisms, Lucid-MS aims to address the underlying causes of disability accumulation that are not captured by relapse rates alone.
The importance of this approach lies in the potential to better treat the progressive nature of MS, which affects millions worldwide. Current therapies often focus on reducing relapses but may not adequately address the ongoing neurodegeneration that leads to permanent disability. By focusing on myelin preservation and functional recovery, Lucid-MS could offer a new avenue for patients who continue to decline despite standard treatments.
Quantum BioPharma's strategy aligns with a broader industry trend toward developing therapies that target the underlying disease process rather than just symptomatic flare-ups. This shift is driven by a better understanding of MS pathophysiology and the recognition that disability progression can occur even without clinical relapses.
The company's newsroom provides updates on QNTM, and more information on the company's developments can be found at https://ibn.fm/QNTM. As research continues, the focus on PIRA and chronic active lesions may lead to new treatment paradigms that could significantly improve long-term outcomes for MS patients.
